October 4, 2018
FDA: Endo Pharmaceuticals recalls two lots of Robaxin
Editor's Note
The Food & Drug Administration on September 28 announced the recall by Endo Pharmaceuticals Inc of two lots of Robaxin 750 mg tablets because of incorrect dosing information on the label.
Robaxin contains methocarbamol, which is used as a muscle relaxant. Patients who follow the incorrect dosing information may experience significant drowsiness and dizziness or they may have an overdose that results in seizures, coma, or death.
To date, the company has not received any reports of adverse events related to the recall.
Free Daily News
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
- Study: Pulse oximeters may misestimate oxygen saturation in darker skin tones
- FDA issues Class 1 recall for vascular cannulas
- Renewed push for healthcare price transparency faces familiar challenges
- Survey: Tariffs expected to increase hospital costs, disrupt supply chains
- Study: Arthroplasty implants linked to metal accumulation in cerebrospinal fluid
- Novel noninvasive surgical approach shows promise in treating severe OCD
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement